Dr. Peter Forsyth, MD

• Neurosurgery

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan-kettering Cancer Center , - Neuro-oncology

  Fellowship Hospital, 1993

• Mayo Clinic - Neurology

  Residency Hospital, 1991

• University Of Toronto, - Medicine

  Internship Hospital, 1988

• Mcmasters University In Ontario

  Medical School, 1984

• Targeted therapy given after anti-PD-1 leads to prolonged responses in mouse melanoma models through sustained antitumor immunity, 2021-03-02

• Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases, 2021-05-25

• Older age at the completion of linear growth is associated with an increased risk of adult glioma, 2017-03-04

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, 2018-08-23

• Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study, 2021-11-10

• Analgesic Use and the Risk of Primary Adult Brain Tumor, 2016-02-19

• Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+Th1 Responses and Potential Use as a Cancer Vaccine, 2021-11-16

• The biology and therapeutic management of melanoma brain metastases, 2017-12-24

• Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies, 2022-03-02

• An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome, 2012-06-28

• Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma, 2020-09-02

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2019-02-19

• Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma, 2020-06-27

• A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature, 2017-04-29

• BIRC3 is a novel driver of therapeutic resistance in Glioblastoma, 2016-02-18

• Toenail iron, genetic determinants of iron status and the risk of glioma, 2013-08-31

• Cellular factors promoting resistance to effective treatment of glioma with oncolytic Myxoma virus, 2014-10-21

• Resistance to Oncolytic Myxoma Virus Therapy in Nf1-/-/Trp53-/-Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon, 2013-06-06

• Capecitabine and stereotactic radiation in the management of breast cancer brain metastases, 2021-05-15

• Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases, 2023-03-21

• Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy, 2016-04-30

• Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases, 2021-03-04

• A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease, 2021-01-29

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2022-09-01

• Myxoma Virus Infection Promotes NK Lysis of Malignant GliomasIn VitroandIn Vivo, 2013-06-10

• Reproductive Factors and Risk of Primary Brain Tumors in Women, 2014-04-04

• Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance, 2020-01-10